中文版 | English
Title

Conversion Surgery Following Immunochemotherapy in Initially Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma-A Real-World Multicenter Study (RICE-Retro)

Author
Corresponding AuthorFu, Junhui; Qiao, Guibin
Publication Years
2022-07-13
DOI
Source Title
ISSN
1664-3224
Volume13
Abstract
PurposeThe present study sets out to evaluate the feasibility, safety, and effectiveness of conversion surgery following induction immunochemotherapy for patients with initially unresectable locally advanced esophageal squamous cell carcinoma (ESCC) in a real-world scenario. Materials and MethodsIn this multi-center, real-world study (NCT04822103), patients who had unresectable ESCC disease were enrolled across eight medical centers in China. All patients received programmed death receptor-1 (PD-1) inhibitor plus chemotherapy every 3 weeks for at least two cycles. Patients with significant relief of cancer-related clinical symptoms and radiological responsive disease were deemed surgical candidates. Feasibility and safety profile of immunochemotherapy plus conversion surgery, radiological and pathological tumor responses, as well as short-term survival outcomes were evaluated. Moreover, data of an independent ESCC cohort receiving induction chemotherapy (iC) were compared. ResultsOne hundred and fifty-five patients were enrolled in the final analysis. Esophagectomy was offered to 116 patients, yielding a conversion rate of 74.8%. R0 resection rate was 94%. Among the 155 patients, 107 (69.0%) patients experienced at least one treatment-related adverse event (TRAE) and 45 (29.0%) patients reported grade 3 and above TRAEs. Significant differences in responsive disease rate were observed between iC cohort and induction immunochemotherapy (iIC) cohort [objective response rate: iIC: 63.2% vs. iC: 47.7%, p = 0.004; pathological complete response: iIC: 22.4% vs. iC: 6.7%, p = 0.001). Higher anastomosis fistula rate was observed in the iC group (19.2%) compared with the iIC group (4%). Furthermore, Significantly higher event-free survival was observed in those who underwent conversion surgery. ConclusionOur results supported that conversion surgery following immunochemotherapy is feasible and safe for patients with initially unresectable locally advanced ESCC. Both radiological and pathological response rates were significantly higher in the iIC cohort compared with those in the traditional iC cohort.
Keywords
URL[Source Record]
Indexed By
Language
English
SUSTech Authorship
Others
WOS Research Area
Immunology
WOS Subject
Immunology
WOS Accession No
WOS:000832803100001
Publisher
Data Source
Web of Science
Citation statistics
Cited Times [WOS]:5
Document TypeJournal Article
Identifierhttp://kc.sustech.edu.cn/handle/2SGJ60CL/365011
DepartmentShenzhen People's Hospital
Affiliation
1.Guangdong Prov Peoples Hosp, Guangdong Acad Med Sci, Dept Thorac Surg, Guangzhou, Peoples R China
2.Shantou Univ Med Coll, Shantou, Peoples R China
3.Shantou Univ, Affiliated Hosp 1, Med Coll, Dept Thorac Surg, Shantou, Peoples R China
4.Sun Yat Sen University, Affiliated Hosp 1, Dept Thorac Surg, Guangzhou, Peoples R China
5.Guangzhou Med Univ, Affiliated Canc Hosp, Dept Thorac Surg, Guangzhou, Peoples R China
6.Gen Hosp Southern Theater Command, Dept Thorac Surg, PLA, Guangzhou, Peoples R China
7.Gaozhou Peoples Hosp, Dept Thorac Surg, Gaozhou, Peoples R China
8.Southern Univ Sci & Technol, Jinan Univ, Shenzhen Peoples Hosp, Affiliated Hosp 1,Shenzhen Inst Resp Dis,Clin Med, Shenzhen, Peoples R China
9.Guangdong Prov Peoples Hosp, Guangdong Acad Med Sci, Dept Pathol, Lab Med, Guangzhou, Peoples R China
10.Shantou Cent Hosp, Dept Surg Oncol, Shantou, Peoples R China
11.Guangdong Prov Peoples Hosp, Guangdong Acad Med Sci, Dept Gen Practice, Guangzhou, Peoples R China
12.Guangdong Prov Peoples Hosp, Guangdong Prov Geriatr Inst, Guangdong Acad Med Sci, Guangzhou, Peoples R China
13.Guangdong Prov Peoples Hosp, Guangdong Acad Med Sci, WeiLun PET Ctr, Dept Nucl Med, Guangzhou, Peoples R China
14.Guangdong Prov Peoples Hosp, Guangdong Acad Med Sci, Dept Oncol, Guangzhou, Peoples R China
15.South China Univ Technol, Sch Med, Chron Dis Lab, Guangzhou, Peoples R China
16.Guangdong Prov Peoples Hosp, Guangdong Acad Med Sci, Dept Radiat Oncol, Guangzhou, Peoples R China
17.Southern Med Univ, Sch Clin Med 2, Guangzhou, Peoples R China
Recommended Citation
GB/T 7714
Huang, Shujie,Wu, Hansheng,Cheng, Chao,et al. Conversion Surgery Following Immunochemotherapy in Initially Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma-A Real-World Multicenter Study (RICE-Retro)[J]. Frontiers in Immunology,2022,13.
APA
Huang, Shujie.,Wu, Hansheng.,Cheng, Chao.,Zhou, Ming.,Xu, Enwu.,...&Qiao, Guibin.(2022).Conversion Surgery Following Immunochemotherapy in Initially Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma-A Real-World Multicenter Study (RICE-Retro).Frontiers in Immunology,13.
MLA
Huang, Shujie,et al."Conversion Surgery Following Immunochemotherapy in Initially Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma-A Real-World Multicenter Study (RICE-Retro)".Frontiers in Immunology 13(2022).
Files in This Item:
There are no files associated with this item.
Related Services
Fulltext link
Recommend this item
Bookmark
Usage statistics
Export to Endnote
Export to Excel
Export to Csv
Altmetrics Score
Google Scholar
Similar articles in Google Scholar
[Huang, Shujie]'s Articles
[Wu, Hansheng]'s Articles
[Cheng, Chao]'s Articles
Baidu Scholar
Similar articles in Baidu Scholar
[Huang, Shujie]'s Articles
[Wu, Hansheng]'s Articles
[Cheng, Chao]'s Articles
Bing Scholar
Similar articles in Bing Scholar
[Huang, Shujie]'s Articles
[Wu, Hansheng]'s Articles
[Cheng, Chao]'s Articles
Terms of Use
No data!
Social Bookmark/Share
No comment.

Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.